Evidence map›Paper›PMID 33369426›Full record

ArticleJournal of medicinal chemistry2021

Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.

Yu Yang, Timothy Borel, Francisco de Azambuja, David Johnson, Jacob P Sorrentino, Chinedum Udokwu, Ian Davis, Aimin Liu, Ryan A Altman

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Boron-Enabled Stereoselective Synthesis of Polysubstituted Housanes.Journal of the American Chemical Society · 2025
    Article
  4. Article
  5. The role of NADnpj metabolic health and disease · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Yu YangDepartment of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States.ORCID 0000-0001-5305-2435
Timothy BorelDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.ORCID 0000-0002-4632-1307
Francisco de AzambujaDepartment of Chemistry, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium.ORCID 0000-0002-5537-5411
David JohnsonComputational Chemical Biology Core and Molecular Graphics and Modeling Laboratory, The University of Kansas, Lawrence, Kansas 66045, United States.
Jacob P SorrentinoDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.ORCID 0000-0001-5071-5379
Chinedum UdokwuDepartment of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States.
Ian DavisDepartment of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States.
Aimin LiuDepartment of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249, United States.ORCID 0000-0002-4182-8176
Ryan A AltmanDepartment of Medicinal Chemistry and Molecular Pharmacology and Department of Chemistry, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-8724-1098
The University of Texas at San Antonio · USUniversity of Kansas · USKU Leuven · BEPurdue University West Lafayette · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Heme-dependent chemistry in tyrosine oxidation: Diversity Supplement on 5R01GM108988-08 for supporting Samuel MontoyaR01GM108988 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI LIU, AIMIN · 2014 to 2025
$4.2M
Grant Supplement to Support Diversity in Health-Related ResearchR35GM124661 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Ryan A Altman · 2017 to 2026
$4.1M
Avance II 500 High Performance Digital NMR Spectrometer SystemS10RR024664 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI VANDERVELDE, DAVID G · 2007 to 2007
$468k
Kynurenine metabolites and depression: An in vitro and ex vivo studyR21MH107985 · NIMH · UNIVERSITY OF TEXAS SAN ANTONIO · PI LIU, AIMIN, SHAMSI, SHAHAB AHMED · 2016 to 2017
$420k
AVIII HD 400 NMR spectrometer to replace existing DRX 400S10OD016360 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DOUGLAS, JUSTIN TRIGALET · 2014 to 2014
$297k
NCRR NIH HHS S10 RR024664NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20 GM113117NIGMS NIH HHS R01 GM108988NIGMS NIH HHS R35 GM124661NIH HHS S10 OD016360NIMH NIH HHS R21 MH107985
6 · The paper itself

Abstract

In the kynurenine pathway for tryptophan degradation, an unstable metabolic intermediate, α-amino-β-carboxymuconate-ε-semialdehyde (ACMS), can nonenzymatically cyclize to form quinolinic acid, the precursor for de novo biosynthesis of nicotinamide adenine dinucleotide (NAD

Indexed as

Bacterial ProteinsBinding SitesBiosynthetic PathwaysCarboxy-LyasesCatalytic DomainCrystallography, X-RayDiflunisalEnzyme InhibitorsHumansInhibitory Concentration 50KynurenineMolecular Docking SimulationNADPseudomonas fluorescensStructure-Activity RelationshipTryptophanBacterial ProteinsCarboxy-LyasesDiflunisalEnzyme InhibitorsKynurenineNADTryptophan

Identifiers

PMID33369426
PMCPMC7856275
OpenAlexW3117153493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.